Journal of Global Oncology · 2017 · 129 citations · 25 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyEndocrine PharmacotherapyBreast Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyHormone Receptor - Positive Breast CancerHormone Receptor Positive Metastatic DiseaseHormone Receptor-positive Breast Cancer TherapyHormone Receptor-positive DiseaseMetastatic Breast Cancer TreatmentSafety Subgroup Analysis
Purpose To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a double-blind phase III study, included 521 patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer with disease progression on endocrine therapy. Patient-reported outcomes (PROs) were assessed on study treatment and at the end of treatment. Results This preplanned subgroup analysis of the PALOMA-3 study included premenopausal and postmenopausal Asians taking palbociclib plus fulvestrant (n = 71) or placebo plus fulvestrant (n = 31). Palbociclib plus fulvestrant improved progression-free survival (PFS) compared with fulvestrant alone. Median PFS was not reached with palbociclib plus fulvestrant (95% CI, 9.2 months to not reached) but was 5.8 months with placebo plus fulvestrant (95% CI, 3.5 to 9.2 months; hazard ratio, 0.485; 95% CI, 0.270 to 0.869; P = .0065). The most common all-cause grade 3 or 4 adverse events in the palbociclib arm were neutropenia (92%) and leukopenia (29%); febrile neutropenia occurred in 4.1% of patients. Within-patient mean trough concentration comparisons across subgroups indicated similar palbociclib exposure between Asians and non-Asians. Global quality of life was maintained; no statistically significant changes from baseline were observed for patient-reported outcome scores with palbociclib plus fulvestrant. Conclusion This is the first report, to our knowledge, showing that palbociclib plus fulvestrant improves PFS in asian patients. Palbociclib plus fulvestrant was well tolerated in this study.
25
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet · 1998 · 4.1K citations
Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations
Medicine, Oncology, Pharmacology +17
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations
Medicine, Oncology, Pharmacology +17